| Bistability analyses of a caspase activation model for receptor-induced apoptosis T Eissing, H Conzelmann, ED Gilles, F Allgower, E Bullinger, P Scheurich Journal of Biological Chemistry 279 (35), 36892-36897, 2004 | 379 | 2004 |
| A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks T Eissing, L Kuepfer, C Becker, M Block, K Coboeken, T Gaub, L Goerlitz, ... Frontiers in physiology 2, 4, 2011 | 249 | 2011 |
| Applied concepts in PBPK modeling: how to build a PBPK/PD model L Kuepfer, C Niederalt, T Wendl, JF Schlender, S Willmann, J Lippert, ... CPT: pharmacometrics & systems pharmacology 5 (10), 516-531, 2016 | 219 | 2016 |
| Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise T Eißing, F Allgöwer, E Bullinger IEE Proceedings-Systems Biology 152 (4), 221-228, 2005 | 103 | 2005 |
| Bistable biological systems: A characterization through local compact input-to-state stability M Chaves, T Eissing, F Allgower IEEE Transactions on Automatic Control 53 (Special Issue), 87-100, 2008 | 98 | 2008 |
| PBPK models for CYP3A4 and P‐gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin N Hanke, S Frechen, D Moj, H Britz, T Eissing, T Wendl, T Lehr CPT: pharmacometrics & systems pharmacology 7 (10), 647-659, 2018 | 93 | 2018 |
| Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals JF Schlender, M Meyer, K Thelen, M Krauss, S Willmann, T Eissing, ... Clinical pharmacokinetics 55, 1573-1589, 2016 | 82 | 2016 |
| Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic … A Dallmann, I Ince, M Meyer, S Willmann, T Eissing, G Hempel Clinical pharmacokinetics 56, 1303-1330, 2017 | 80 | 2017 |
| First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development A Strougo, T Eissing, A Yassen, S Willmann, M Danhof, J Freijer Journal of pharmacokinetics and pharmacodynamics 39, 195-203, 2012 | 75 | 2012 |
| A generic integrated physiologically based whole‐body model of the glucose‐insulin‐glucagon regulatory system S Schaller, S Willmann, J Lippert, L Schaupp, TR Pieber, A Schuppert, ... CPT: pharmacometrics & systems pharmacology 2 (8), 1-10, 2013 | 74 | 2013 |
| Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women A Dallmann, I Ince, J Solodenko, M Meyer, S Willmann, T Eissing, ... Clinical pharmacokinetics 56, 1525-1541, 2017 | 64 | 2017 |
| A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim C Niederalt, L Kuepfer, J Solodenko, T Eissing, HU Siegmund, M Block, ... Journal of pharmacokinetics and pharmacodynamics 45, 235-257, 2018 | 60 | 2018 |
| Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models A Dallmann, M Pfister, J van den Anker, T Eissing Clinical Pharmacology & Therapeutics 104 (6), 1110-1124, 2018 | 58 | 2018 |
| Dynamics on and of complex networks N Ganguly, A Deutsch, A Mukherjee Applications to Biology, Computer Science, and the Social Sciences, 2009 | 54 | 2009 |
| A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways A Dallmann, I Ince, K Coboeken, T Eissing, G Hempel Clinical pharmacokinetics 57, 749-768, 2018 | 53 | 2018 |
| Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores T Eissing, S Waldherr, F Allgöwer, P Scheurich, E Bullinger Biophysical journal 92 (9), 3332, 2007 | 53 | 2007 |
| Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 … T Eissing, J Lippert, S Willmann Molecular diagnosis & therapy 16, 43-53, 2012 | 44 | 2012 |
| Steady state and (bi-) stability evaluation of simple protease signalling networks T Eißing, S Waldherr, F Allgöwer, P Scheurich, E Bullinger Biosystems 90 (3), 591-601, 2007 | 43 | 2007 |
| Mechanistic oral absorption modeling and simulation for formulation development and bioequivalence evaluation: report of an FDA public workshop X Zhang, J Duan, F Kesisoglou, J Novakovic, GL Amidon, M Jamei, ... CPT: Pharmacometrics & Systems Pharmacology 6 (8), 492-495, 2017 | 38 | 2017 |
| Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance K Dickschen, S Willmann, K Thelen, J Lippert, G Hempel, T Eissing Frontiers in Pharmacology 3, 92, 2012 | 36 | 2012 |
Stefan WillmannBayer AGVerified email at drwillmann.de
